Polar Capital’s Bellicum Pharmaceuticals, Inc. BLCM Stock Holding History

Polar Capital’s Portfolio BLCM Stock Details BLCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-1,105	Closed	-$235K	–	297
2015 Q2	$235K	Buy	+1,105	New	+$271K	﹤0.01%	280

Other funds holding BLCM

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Polar Capital's BLCM Position: Q3 2015 in Review

Polar Capital sold out of Bellicum Pharmaceuticals, Inc. (BLCM) in Q3 2015, closing a stake of 1,105 shares — an estimated $235K sold.

Polar Capital first reported a position in BLCM in Q2 2015 and held it in 1 quarter. The position peaked at $235K in Q2 2015. 83 funds tracked by Wall St. Rank hold BLCM as of Q3 2015.

Polar Capital reported no remaining Bellicum Pharmaceuticals, Inc. position as of Q3 2015 after selling out during the quarter.
Polar Capital sold 1,105 Bellicum Pharmaceuticals, Inc. shares in Q3 2015, an estimated $235K.
Polar Capital first reported a position in Bellicum Pharmaceuticals, Inc. in Q2 2015 and held it in 1 quarter.
Polar Capital's Bellicum Pharmaceuticals, Inc. position peaked at $235K in Q2 2015.
83 funds tracked by Wall St. Rank held Bellicum Pharmaceuticals, Inc. as of Q3 2015.

Based on Polar Capital's 13F filing for Q3 2015, filed 16 Nov 2015.